{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:24:58Z","timestamp":1790504698410,"version":"4.1.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40259-019-00368-z","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T09:02:53Z","timestamp":1564477373000},"page":"515-537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies"],"prefix":"10.1007","volume":"33","author":[{"given":"Lorraine","family":"Springuel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9230-3855","authenticated-orcid":false,"given":"Caroline","family":"Lonez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pascal H.","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Van Den Eynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Hendlisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Shaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Canon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Opyrchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunle","family":"Odunsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gilham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Flament","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric F.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"368_CR1","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"368_CR2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor (CAR) design. Cancer Discov. 2013;3:388\u201398.","journal-title":"Cancer Discov."},{"key":"368_CR3","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/ajh.25398","volume":"94","author":"MB Leick","year":"2019","unstructured":"Leick MB, Maus MV. CAR-T cells beyond CD19, UnCAR-Ted territory. Am J Hematol. 2019;94:S34\u201341.","journal-title":"Am J Hematol."},{"key":"368_CR4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s11899-018-0482-6","volume":"13","author":"R Havard","year":"2018","unstructured":"Havard R, Stephens DM. Anti-CD19 chimeric antigen receptor T cell therapies: harnessing the power of the immune system to fight diffuse large B cell lymphoma. Curr Hematol Malig Rep. 2018;13:534\u201342.","journal-title":"Curr Hematol Malig Rep."},{"key":"368_CR5","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"R Brentjens","year":"2013","unstructured":"Brentjens R, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.","journal-title":"Sci Transl Med."},{"key":"368_CR6","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.","journal-title":"Sci Transl Med."},{"key":"368_CR7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139.","journal-title":"J Clin Oncol."},{"key":"368_CR8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med."},{"key":"368_CR9","unstructured":"European Medicines Agency. Yescarta. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yescarta . Accessed 25 Apr 2019."},{"key":"368_CR10","unstructured":"U.S. Food and Drug Administration. Approved products\u2014YESCARTA (axicabtagene ciloleucel). https:\/\/www.fda.gov\/biologicsbloodvaccines\/cellulargenetherapyproducts\/approvedproducts\/ucm581222.htm . Accessed 25 Apr 2019."},{"key":"368_CR11","unstructured":"European Medicines Agency. Kymriah. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kymriah . Accessed 25 Apr 2019."},{"key":"368_CR12","unstructured":"U.S. Food and Drug Administration. Approved Products\u2014KYMRIAH (tisagenlecleucel). https:\/\/www.fda.gov\/biologicsbloodvaccines\/cellulargenetherapyproducts\/approvedproducts\/ucm573706.htm . Accessed 25 Apr 2019."},{"key":"368_CR13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med."},{"key":"368_CR14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med."},{"key":"368_CR15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31:311\u201325.","journal-title":"Cancer Cell."},{"key":"368_CR16","doi-asserted-by":"crossref","first-page":"e970027","DOI":"10.4161\/21624011.2014.970027","volume":"3","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. OncoImmunology. 2014;3:e970027.","journal-title":"OncoImmunology."},{"key":"368_CR17","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","volume":"20","author":"EK Moon","year":"2014","unstructured":"Moon EK, Wang L-C, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res. 2014;20:4262\u201373.","journal-title":"Clin Cancer Res."},{"key":"368_CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fonc.2017.00003","volume":"7","author":"N Ramamonjisoa","year":"2017","unstructured":"Ramamonjisoa N, Ackerstaff E. Characterization of the tumor microenvironment and tumor\u2013stroma interaction by non-invasive preclinical imaging. Front Oncol. 2017;7:3.","journal-title":"Front Oncol."},{"key":"368_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","volume":"33","author":"MC Jensen","year":"2015","unstructured":"Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol. 2015;33:9\u201315.","journal-title":"Curr Opin Immunol."},{"key":"368_CR20","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.3389\/fimmu.2018.03084","volume":"9","author":"R Sackstein","year":"2019","unstructured":"Sackstein R. The first step in adoptive cell immunotherapeutics: assuring cell delivery via glycoengineering. Front Immunol. 2019;9:3084.","journal-title":"Front Immunol."},{"key":"368_CR21","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR21 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113:6392\u2013402.","journal-title":"Blood."},{"key":"368_CR22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR22b. J Immunother. 2010;33:780\u20138.","journal-title":"J Immunother."},{"key":"368_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120:26\u201337.","journal-title":"Br J Cancer."},{"issue":"7","key":"368_CR24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/cancers9070092","volume":"9","author":"P Sridhar","year":"2017","unstructured":"Sridhar P, Petrocca F. Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy. Cancers (Basel). 2017;9(7):92.","journal-title":"Cancers (Basel)."},{"key":"368_CR25","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10875-011-9532-8","volume":"31","author":"AC Parente-Pereira","year":"2011","unstructured":"Parente-Pereira AC, Burnet J, Ellison D, Foster J, Davies DM, van der Stegen S, et al. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol. 2011;31:710\u20138.","journal-title":"J Clin Immunol."},{"key":"368_CR26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","volume":"23","author":"S Katz","year":"2016","unstructured":"Katz S, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 2016;23:142\u20138.","journal-title":"Cancer Gene Ther."},{"key":"368_CR27","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6:261ra151.","journal-title":"Sci Transl Med."},{"key":"368_CR28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12:813\u201320.","journal-title":"Nat Nanotechnol."},{"key":"368_CR29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275\u201387.","journal-title":"Nat Rev Cancer."},{"key":"368_CR30","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CPM, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636\u201346.","journal-title":"Clin Cancer Res."},{"key":"368_CR31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.intimp.2019.01.010","volume":"70","author":"L Wang","year":"2019","unstructured":"Wang L, Yao R, Zhang L, Fan C, Ma L, Liu J. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: combination and opportunity. Int Immunopharmacol. 2019;70:498\u2013503.","journal-title":"Int Immunopharmacol."},{"key":"368_CR32","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Investig. 2016;126:3130\u201344.","journal-title":"J Clin Investig."},{"key":"368_CR33","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26:1855\u201366.","journal-title":"Mol Ther."},{"issue":"4","key":"368_CR34","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI121491","volume":"129","author":"TN Yamamoto","year":"2019","unstructured":"Yamamoto TN, Lee P-H, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest. 2019;129(4):1551\u201365.","journal-title":"J Clin Invest."},{"key":"368_CR35","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737.","journal-title":"Sci Rep."},{"key":"368_CR36","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847\u201356.","journal-title":"Nat Biotechnol."},{"key":"368_CR37","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014;22:1211\u201320.","journal-title":"Mol Ther."},{"key":"368_CR38","first-page":"460","volume":"7","author":"X Tang","year":"2015","unstructured":"Tang X, Li Q, Zhu Y, Zheng D, Dai J, Ni W, et al. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1+ cancer therapy. Am J Transl Res. 2015;7:460\u201373.","journal-title":"Am J Transl Res."},{"key":"368_CR39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25:249\u201358.","journal-title":"Mol Ther."},{"key":"368_CR40","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76:1578\u201390.","journal-title":"Cancer Res."},{"key":"368_CR41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257:83\u201390.","journal-title":"Immunol Rev."},{"key":"368_CR42","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J, et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 2017;20:3025\u201333.","journal-title":"Cell Rep."},{"issue":"3","key":"368_CR43","doi-asserted-by":"crossref","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3):e994446.","journal-title":"Oncoimmunology."},{"key":"368_CR44","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7:10541.","journal-title":"Sci Rep."},{"key":"368_CR45","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 2017;21:3205\u201319.","journal-title":"Cell Rep."},{"key":"368_CR46","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3389\/fimmu.2018.01740","volume":"9","author":"HM Knochelmann","year":"2018","unstructured":"Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM. CAR T cells in solid tumors: blueprints for building effective therapies. Front Immunol. 2018;9:1740.","journal-title":"Front Immunol."},{"key":"368_CR47","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71:5697\u2013706.","journal-title":"Cancer Res."},{"key":"368_CR48","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-\u03b3 production. Blood. 1997;90:2541\u20138.","journal-title":"Blood."},{"key":"368_CR49","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, et al. Tumor infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015;21:2278\u201388.","journal-title":"Clin Cancer Res."},{"key":"368_CR50","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-07-4740","volume":"14","author":"MJ Robertson","year":"2008","unstructured":"Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, et al. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008;14:3462\u20139.","journal-title":"Clin Cancer Res."},{"key":"368_CR51","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","volume":"6","author":"N Siriwon","year":"2018","unstructured":"Siriwon N, Kim YJ, Siegler E, Chen X, Rohrs JA, Liu Y, et al. CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol Res. 2018;6:812\u201324.","journal-title":"Cancer Immunol Res."},{"key":"368_CR52","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med."},{"key":"368_CR53","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333.","journal-title":"N Engl J Med."},{"key":"368_CR54","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","volume":"23","author":"ZL Chang","year":"2017","unstructured":"Chang ZL, Chen YY. CARs: Synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med. 2017;23:430\u201350.","journal-title":"Trends Mol Med."},{"key":"368_CR55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/cancers11010029","volume":"11","author":"S Lorenzo-Herrero","year":"2018","unstructured":"Lorenzo-Herrero S, L\u00f3pez-Soto A, Sordo-Bahamonde C, Gonzalez-Rodriguez A, Vitale M, Gonzalez S. NK cell-based immunotherapy in cancer metastasis. Cancers. 2018;11:29.","journal-title":"Cancers."},{"key":"368_CR56","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T-cell subset with stem cell-like properties. Nat Med. 2011;17:1290\u20137.","journal-title":"Nat Med."},{"key":"368_CR57","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3389\/fimmu.2018.02740","volume":"9","author":"KB Long","year":"2018","unstructured":"Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF, et al. CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success. Front Immunol. 2018;9:2740.","journal-title":"Front Immunol."},{"key":"368_CR58","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi S, Nunez-Cruz S, O\u2019Connor RS, Fraietta JA, Patel PR, Scholler J, et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T Cells. Cancer Immunol Res. 2018;6:1100\u20139.","journal-title":"Cancer Immunol Res."},{"key":"368_CR59","doi-asserted-by":"crossref","first-page":"35807","DOI":"10.18632\/oncotarget.26334","volume":"9","author":"W Zheng","year":"2018","unstructured":"Zheng W, Jones LL, Geiger TL. Modulation of PI3K signaling to improve CAR T cell function. Oncotarget. 2018;9:35807\u20138.","journal-title":"Oncotarget."},{"key":"368_CR60","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","volume":"132","author":"N Shah","year":"2018","unstructured":"Shah N, Alsina M, Siegel DS, Jagannath S, Madduri D, Kaufman JL, Turka A, Lam LP, Massaro M, Hege K, Petrocca F, Berdeja JG, Raje N. Initial results from a phase 1 clinical study of bb21217, a next-generation Anti Bcma CAR T therapy. Blood 2018; 132:488. https:\/\/doi.org\/10.1182\/blood-2018-99-116953","journal-title":"Blood"},{"key":"368_CR61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","volume":"121","author":"N Cieri","year":"2013","unstructured":"Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121:573\u201384.","journal-title":"Blood."},{"key":"368_CR62","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123:3750\u20139.","journal-title":"Blood."},{"key":"368_CR63","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2326-6066.CIR-14-0200","volume":"3","author":"A K\u00fcnkele","year":"2015","unstructured":"K\u00fcnkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, et al. Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas\u2013FasL-dependent AICD. Cancer Immunol Res. 2015;3:368\u201379.","journal-title":"Cancer Immunol Res."},{"key":"368_CR64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28:415\u201328.","journal-title":"Cancer Cell."},{"key":"368_CR65","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht J, Sun J, Eyquem J, Ho Y-J, Zhao Z, Leibold J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med. 2019;25:82.","journal-title":"Nat Med."},{"issue":"8","key":"368_CR66","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","volume":"4","author":"R Sakemura","year":"2016","unstructured":"Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, et al. A Tet-On inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol Res. 2016;4(8):658\u201368.","journal-title":"Cancer Immunol Res."},{"key":"368_CR67","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.21037\/tcr.2016.06.04","volume":"5","author":"DM Davies","year":"2016","unstructured":"Davies DM, Maher J. Gated chimeric antigen receptor T-cells: the next logical step in reducing toxicity? Transl Cancer Res. 2016;5:S61\u20135.","journal-title":"Transl Cancer Res."},{"key":"368_CR68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31:71\u20135.","journal-title":"Nat Biotechnol."},{"key":"368_CR69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","volume":"1","author":"E Lanitis","year":"2013","unstructured":"Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013;1:43\u201353.","journal-title":"Cancer Immunol Res."},{"key":"368_CR70","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215ra172.","journal-title":"Sci Transl Med."},{"key":"368_CR71","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.4049\/jimmunol.0902000","volume":"183","author":"A Barber","year":"2009","unstructured":"Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol. 2009;183:6939\u201347.","journal-title":"J Immunol."},{"issue":"18","key":"368_CR72","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2217\/fon-2017-0102","volume":"13","author":"B Demoulin","year":"2017","unstructured":"Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman M-L, Lonez C, et al. Exploiting natural killer group 2D receptors for CAR T-cell therapy. Future Oncol. 2017;13(18):1593\u2013605.","journal-title":"Future Oncol."},{"key":"368_CR73","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.4049\/jimmunol.1201314","volume":"190","author":"T Zhang","year":"2013","unstructured":"Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol. 2013;190:2455\u201363.","journal-title":"J Immunol."},{"key":"368_CR74","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/imt.14.120","volume":"7","author":"LM Whilding","year":"2015","unstructured":"Whilding LM, Maher J. ErbB-targeted CAR T-cell immunotherapy of cancer. Immunotherapy. 2015;7:229\u201341.","journal-title":"Immunotherapy."},{"key":"368_CR75","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/imt-2017-0045","volume":"9","author":"DE Gilham","year":"2017","unstructured":"Gilham DE, Maher J. \u2018Atypical\u2019 CAR T cells: NKG2D and Erb-B as examples of natural receptor\/ligands to target recalcitrant solid tumors. Immunotherapy. 2017;9:723\u201333.","journal-title":"Immunotherapy."},{"key":"368_CR76","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2119\/molmed.2011.00493","volume":"18","author":"DM Davies","year":"2012","unstructured":"Davies DM, Foster J, van der Stegen SJ, Parente-Pereira AC, Chiapero-Stanke L, Delinassios GJ, et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med. 2012;18:565.","journal-title":"Mol Med."},{"key":"368_CR77","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","volume":"393","author":"A Klampatsa","year":"2017","unstructured":"Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, et al. Intracavitary \u201cT4 immunotherapy\u201d of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells. Cancer Lett. 2017;393:52\u20139.","journal-title":"Cancer Lett."},{"key":"368_CR78","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"L Labanieh","year":"2018","unstructured":"Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2:377\u201391.","journal-title":"Nat Biomed Eng."},{"key":"368_CR79","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","volume":"116","author":"YJ Xie","year":"2019","unstructured":"Xie YJ, Dougan M, Jailkhani N, Ingram J, Fang T, Kummer L, et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci. 2019;116:7624\u201331.","journal-title":"Proc Natl Acad Sci."},{"key":"368_CR80","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res. 2014;2:112\u201320.","journal-title":"Cancer Immunol Res."},{"key":"368_CR81","doi-asserted-by":"crossref","first-page":"e0128151","DOI":"10.1371\/journal.pone.0128151","volume":"10","author":"DC Deniger","year":"2015","unstructured":"Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, et al. Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations. PLOS One. 2015;10:e0128151.","journal-title":"PLOS One."},{"key":"368_CR82","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"L-CS Wang","year":"2014","unstructured":"Wang L-CS, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2:154\u201366.","journal-title":"Cancer Immunol Res."},{"key":"368_CR83","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2015.09.022","volume":"28","author":"IM Stromnes","year":"2015","unstructured":"Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen HN, Cuevas C, et al. T Cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell. 2015;28:638\u201352.","journal-title":"Cancer Cell."},{"key":"368_CR84","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","volume":"126","author":"PJ Paszkiewicz","year":"2016","unstructured":"Paszkiewicz PJ, Fr\u00e4\u00dfle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Investig. 2016;126:4262\u201372.","journal-title":"J Clin Investig."},{"key":"368_CR85","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood. 2014;124:1277\u201387.","journal-title":"Blood."},{"key":"368_CR86","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pul\u00e8 MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105:4247\u201354.","journal-title":"Blood."},{"key":"368_CR87","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci USA. 2016;113:E459\u201368.","journal-title":"Proc Natl Acad Sci USA"},{"key":"368_CR88","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1073\/pnas.1524193113","volume":"113","author":"JSY Ma","year":"2016","unstructured":"Ma JSY, Kim JY, Kazane SA, Choi S, Yun HY, Kim MS, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci USA. 2016;113:E450\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"key":"368_CR89","first-page":"1426.e11","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173:1426.e11\u20131438.e11.","journal-title":"Cell."},{"key":"368_CR90","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1038\/bcj.2016.61","volume":"6","author":"M Cartellieri","year":"2016","unstructured":"Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6:e458.","journal-title":"Blood Cancer J."},{"key":"368_CR91","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","volume":"18","author":"K Tamada","year":"2012","unstructured":"Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012;18:6436\u201345.","journal-title":"Clin Cancer Res."},{"key":"368_CR92","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","volume":"72","author":"K Urbanska","year":"2012","unstructured":"Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72:1844\u201352.","journal-title":"Cancer Res."},{"key":"368_CR93","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai H, Reik A, Liu P-Q, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119:5697\u2013705.","journal-title":"Blood."},{"key":"368_CR94","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. 2013;122:1341\u20139.","journal-title":"Blood."},{"key":"368_CR95","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas D, Hannon GJ. Patient derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73:5315\u20139.","journal-title":"Cancer Res."},{"issue":"3","key":"368_CR96","doi-asserted-by":"crossref","first-page":"FSO271","DOI":"10.4155\/fsoa-2017-0136","volume":"4","author":"E Yada","year":"2018","unstructured":"Yada E, Wada S, Yoshida S, Sasada T. Use of patient-derived xenograft mouse models in cancer research and treatment. Future Sci OA. 2018;4(3):FSO271.","journal-title":"Future Sci OA."},{"key":"368_CR97","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","volume":"117","author":"CHJ Lamers","year":"2011","unstructured":"Lamers CHJ, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood. 2011;117:72\u201382.","journal-title":"Blood."},{"key":"368_CR98","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00262-007-0330-3","volume":"56","author":"CHJ Lamers","year":"2007","unstructured":"Lamers CHJ, Langeveld SCL, Groot-van Ruijven CM, Debets R, Sleijfer S, Gratama JW. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother. 2007;56:1875\u201383.","journal-title":"Cancer Immunol Immunother."},{"key":"368_CR99","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843\u201351.","journal-title":"Mol Ther."},{"key":"368_CR100","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang W-C, et al. Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21:4062\u201372.","journal-title":"Clin Cancer Res."},{"key":"368_CR101","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561\u20139.","journal-title":"N Engl J Med."},{"issue":"8","key":"368_CR102","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, et al. HER2-specific chimeric antigen receptor\u2013modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094\u2013101.","journal-title":"JAMA Oncol."},{"key":"368_CR103","doi-asserted-by":"crossref","unstructured":"Adusumilli PS, Zauderer MG, Rusch V, O\u2019Cearbhaill RE, Zhu A, Ngai D, et al. A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy [abstract no. CT036]. AACR annual meeting, Atlanta; 2019. https:\/\/www.abstractsonline.com\/pp8\/#!\/6812\/presentation\/9837 . Accessed 3 May 2019.","DOI":"10.1158\/1538-7445.AM2019-CT036"},{"issue":"4_suppl","key":"368_CR104","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2019.37.4_suppl.283","volume":"37","author":"Carlos Roberto Becerra","year":"2019","unstructured":"Becerra CR, Hoof P, Paulson AS, Manji GA, Gardner O, Malankar A, et al. Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: preliminary results from a dose escalation [abstract no. 283]. J Clin Oncol. 2019;37(4 Suppl):283. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2019.37.4_suppl.283 . Accessed 16 May 2019.","journal-title":"Journal of Clinical Oncology"},{"key":"368_CR105","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","volume":"15","author":"JR Park","year":"2007","unstructured":"Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther J Am Soc Gene Ther. 2007;15:825\u201333.","journal-title":"Mol Ther J Am Soc Gene Ther."},{"key":"368_CR106","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264\u201370.","journal-title":"Nat Med."},{"key":"368_CR107","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor\u2013positive T cells in patients with neuroblastoma. Blood. 2011;118:6050\u20136.","journal-title":"Blood."},{"key":"368_CR108","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2013.144","volume":"24","author":"MCI van Schalkwyk","year":"2013","unstructured":"van Schalkwyk MCI, Papa SE, Jeannon J-P, Urbano TG, Spicer JF, Maher J. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev. 2013;24:134\u201342.","journal-title":"Hum Gene Ther Clin Dev."},{"key":"368_CR109","first-page":"365","volume-title":"Methods in Molecular Biology","author":"Sophie Papa","year":"2015","unstructured":"Papa S, van Schalkwyk M, Maher J. Clinical evaluation of ErbB-targeted CAR T-cells, following intracavity delivery in patients with ErbB-expressing solid tumors. In: Walther W, Stein U, editors. Gene therapy of solid cancers. New York: Springer; 2015. pp. 365\u201382. http:\/\/link.springer.com\/10.1007\/978-1-4939-2727-2_21 . Accessed 16 Mar 2016."},{"key":"368_CR110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.retram.2018.03.001","volume":"66","author":"C Lonez","year":"2018","unstructured":"Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, et al. Celyad\u2019s novel CAR T-cell therapy for solid malignancies. Curr Res Transl Med. 2018;66:53\u20136.","journal-title":"Curr Res Transl Med."},{"key":"368_CR111","unstructured":"Hendlisz A. Results and perspectives from phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors [abstract no. P255]. Society of Immunotherapy Cancer (SITC) 2018; 7\u201311 Nov 2018; Washington, DC."},{"key":"368_CR112","first-page":"3425291","volume":"2019","author":"B Hou","year":"2019","unstructured":"Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis. Dis Markers. 2019;2019:3425291.","journal-title":"Dis Markers."},{"key":"368_CR113","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33:1688\u201396.","journal-title":"J Clin Oncol."},{"key":"368_CR114","doi-asserted-by":"crossref","unstructured":"Navai SA, DeRenzo C, Joseph SK, Sanber K, Byrd T, Zhang H, et al. Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas [abstract no. LB-147\/4]. 2019. https:\/\/www.abstractsonline.com\/pp8\/#!\/6812\/presentation\/9413 . Accessed 3 May 2019.","DOI":"10.1158\/1538-7445.AM2019-LB-147"},{"key":"368_CR115","doi-asserted-by":"crossref","first-page":"O11","DOI":"10.1186\/2051-1426-3-S2-O11","volume":"3","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Brawley V, Hegde M, Bielamowicz K, Wakefield A, Ghazi A, et al. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a phase I trial. J Immunother Cancer. 2015;3:O11.","journal-title":"J Immunother Cancer."},{"key":"368_CR116","doi-asserted-by":"crossref","first-page":"CT145","DOI":"10.1158\/1538-7445.AM2018-CT145","volume":"78","author":"K Straathof","year":"2018","unstructured":"Straathof K, Flutter B, Wallace R, Thomas S, Cheung G, Collura A, et al. A Cancer Research UK phase I trial of anti-GD2 chimeric antigen receptor (CAR) transduced T-cells (1RG-CART) in patients with relapsed or refractory neuroblastoma. Cancer Res. 2018;78:CT145.","journal-title":"Cancer Res."},{"key":"368_CR117","unstructured":"Bellicum. Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T\u00ae cells in advanced solid tumors: preliminary results from a dose escalation study [abstract no. 320]. ESMO 2018. http:\/\/www.bellicum.com\/wp-content\/uploads\/2018\/12\/ESMO-IO-2018_Becerra-et-al_Abstract-320_Final-Presentation.pdf . Accessed 27 Jul 2019."},{"key":"368_CR118","doi-asserted-by":"crossref","unstructured":"Zhan X, Wang B, Li Z, Li J, Wang H, Chen L, et al. Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma [abstract no. 2509]. ASCO 2019 annual meeting. https:\/\/meetinglibrary.asco.org\/record\/172418\/abstract . Accessed 17 May 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.2509"},{"key":"368_CR119","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1200\/JCO.2017.35.15_suppl.3049","volume":"35","author":"B Zhai","year":"2017","unstructured":"Zhai B, Shi D, Gao H, Qi X, Jiang H, Zhang Y, et al. A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r\/r GPC3+ HCC) [abstract no. 3049]. J Clin Oncol. 2017;35:3049.","journal-title":"J Clin Oncol."},{"issue":"6","key":"368_CR120","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","volume":"24","author":"Y Guo","year":"2018","unstructured":"Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q, et al. Phase I study of chimeric antigen receptor modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res. 2018;24(6):1277\u201386.","journal-title":"Clin Cancer Res."},{"issue":"5","key":"368_CR121","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","volume":"59","author":"K Feng","year":"2016","unstructured":"Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59(5):468\u201379. https:\/\/doi.org\/10.1007\/s11427-016-5023-8 .","journal-title":"Sci China Life Sci."},{"key":"368_CR122","doi-asserted-by":"crossref","first-page":"e017075","DOI":"10.1136\/bmjopen-2017-017075","volume":"7","author":"C Lonez","year":"2017","unstructured":"Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, et al. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 2017;7:e017075.","journal-title":"BMJ Open."},{"key":"368_CR123","unstructured":"Eureka Therapeutics. Eureka Therapeutics achieves regression of metastatic liver cancer using ET140202 T-cell therapy. https:\/\/www.eurekatherapeutics.com\/media\/press-releases\/090518\/ . Accessed 22 Mar 2019."},{"key":"368_CR124","doi-asserted-by":"crossref","first-page":"CT131","DOI":"10.1158\/1538-7445.AM2018-CT131","volume":"78","author":"JM Specht","year":"2018","unstructured":"Specht JM, Lee S, Turtle CJ, Berger C, Baladrishnan A, Srivastava S, et al. A phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR). Cancer Res. 2018;78:CT131.","journal-title":"Cancer Res."},{"key":"368_CR125","doi-asserted-by":"crossref","unstructured":"Specht JM, et al. A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR) [poster no. P2-09-13]. San Antonio breast cancer symposium (SABCS); 4\u20138 Dec 2018; San Antonio.","DOI":"10.1158\/1538-7445.SABCS18-P2-09-13"},{"key":"368_CR126","unstructured":"Moroz K. Anti-CEA CAR-T demonstrates significant therapeutic effect in pancreatic cancer patients with liver metastases. Interventional Oncology. 2018. https:\/\/www.interventionaloncology360.com\/news\/anti-cea-car-t-demonstrates-significant-therapeutic-effect-pancreatic-cancer-patients-liver . Accessed 16 May 2019."},{"key":"368_CR127","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","volume":"21","author":"SC Katz","year":"2015","unstructured":"Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21:3149\u201359.","journal-title":"Clin Cancer Res."},{"key":"368_CR128","doi-asserted-by":"crossref","first-page":"CT109","DOI":"10.1158\/1538-7445.AM2017-CT109","volume":"77","author":"SC Katz","year":"2017","unstructured":"Katz SC, Prince E, Cunetta M, Guha P, Moody A, Armenio V, et al. HITM-SIR: Phase Ib trial of CAR-T hepatic artery infusions and selective internal radiation therapy for liver metastases [abstract no. CT109]. Cancer Res. 2017;77:CT109.","journal-title":"Cancer Res."},{"key":"368_CR129","volume-title":"Cancer facts & figures\u00a02019","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society. Cancer facts & figures\u00a02019. Atlanta: American Cancer Society; 2019."},{"issue":"15_suppl","key":"368_CR130","doi-asserted-by":"publisher","first-page":"10508","DOI":"10.1200\/JCO.2017.35.15_suppl.10508","volume":"35","author":"M Hegde","year":"2017","unstructured":"Hegde M, DeRenzo CC, Zhang H, Mata M, Gerken C, Shree A, Yi Z, Brawley V, Dakhova O, Wu M-F, Liu H, Hicks F, Grilley B, Gee AP, Rooney CM, Brenner MK, Heslop HE, Wels W, Gottschalk S, Ahmed NM. Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma. J Clin Oncol. 2017;35(15_suppl):10508. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.10508","journal-title":"J Clin Oncol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00368-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-019-00368-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00368-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T21:03:16Z","timestamp":1664053396000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-019-00368-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1007\/s40259-019-00368-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]},"assertion":[{"value":"30 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lorraine Springuel, Caroline Lonez, Bertrand Alexandre, David E. Gilham, Anne Flament, and Fr\u00e9d\u00e9ric F. Lehmann are employees of Celyad SA. Mateusz Opyrchal has consulting agreements with Novartis and AstraZeneca, and has received research funding from Pfizer and Bayer. Eric Van Cutsem reports participation in advisory boards for AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, and Servier and research grants from Amgen, Bayer, Boehringer Ingelheim, Celgene, Ipsen, Lilly, Roche, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, and Servier paid to his institution (Cliniques Universitaires Saint-Luc) outside the submitted work. Jean-Pascal H. Machiels, Marc Van Den Eynde, Hans Prenen, Alain Hendlisz, Eric Van Cutsem, Leila Shaza, Javier Carrasco, Jean-Luc Canon, Mateusz Opyrchal, Kunle Odunsi, and Sylvie Rottey are investigators on Celyad\u2019s sponsored trials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}